Payment overview · 2025
General Payments
$96.84
5 reported records · 4 companies
Healthcare provider profile · identity verified
Todd A. Sorensen, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX FALLS, SD · NPI 1104826692
Verified facts
What the public records show
CMS Open Payments records show Todd A. Sorensen, MD received $96.84 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.94 | 38.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.23 | 24.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.93 | 20.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.74 | 17.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $96.84 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 147 |
| Omeprazole | Omeprazole | 536 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 453 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 450 | 117 |
| Gabapentin | Gabapentin | 443 | 75 |
| Losartan Potassium | Losartan Potassium | 405 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 399 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 343 | 73 |
| Lisinopril | Lisinopril | 331 | 83 |
| Furosemide | Furosemide | 282 | 73 |
| Sertraline Hcl | Sertraline Hcl | 268 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 66 |
| Potassium Chloride | Potassium Chloride | 228 | 51 |
| Eliquis | Apixaban | 225 | 31 |
| Trazodone Hcl | Trazodone Hcl | 223 | 50 |
| Metformin Hcl | Metformin Hcl | 222 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 49 |
| Metformin Hcl Er | Metformin Hcl | 201 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 38 |
| Simvastatin | Simvastatin | 164 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 35 |
| Alprazolam | Alprazolam | 156 | 27 |
| Donepezil Hcl | Donepezil Hcl | 154 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 33 |
| Clonazepam | Clonazepam | 150 | 28 |
| Montelukast Sodium | Montelukast Sodium | 147 | 30 |
| Allopurinol | Allopurinol | 144 | 34 |
| Tramadol Hcl | Tramadol Hcl | 137 | 33 |
| Ozempic | Semaglutide | 134 | 26 |
| Meloxicam | Meloxicam | 125 | 33 |
| Glipizide | Glipizide | 121 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 50 |
| Glimepiride | Glimepiride | 118 | 27 |
| Finasteride | Finasteride | 112 | 24 |
| Bupropion Xl | Bupropion Hcl | 111 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 105 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 25 |
| Pregabalin | Pregabalin | 99 | 22 |
| Mirtazapine | Mirtazapine | 98 | 16 |
| Lorazepam | Lorazepam | 97 | 25 |
| Spironolactone | Spironolactone | 93 | 28 |
| Bumetanide | Bumetanide | 92 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 20 |
| Famotidine | Famotidine | 87 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 22 |
| Atenolol | Atenolol | 76 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 17 |
| Lamotrigine | Lamotrigine | 75 | 13 |
| Memantine Hcl | Memantine Hcl | 75 | 11 |
| Mounjaro | Tirzepatide | 71 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 13 |
| Topiramate | Topiramate | 64 | 15 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Jantoven | Warfarin Sodium | 63 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 13 |
| Ondansetron Odt | Ondansetron | 58 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 14 |
| Carvedilol | Carvedilol | 57 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 56 | suppressed |
| Prednisone | Prednisone | 56 | 36 |
| Azithromycin | Azithromycin | 54 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Aripiprazole | Aripiprazole | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 17 |
| Warfarin Sodium | Warfarin Sodium | 41 | 11 |
| Amoxicillin | Amoxicillin | 40 | 28 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 27 |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Carisoprodol | Carisoprodol | 38 | suppressed |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 12 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Nabumetone | Nabumetone | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 31 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 23 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Savella | Milnacipran Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Mesalamine | Mesalamine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 13 |
| Estradiol | Estradiol | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Buprenorphine | Buprenorphine | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 14 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Diazepam | Diazepam | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Felbamate | Felbamate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $96.84 · 5 records | Amgen Inc. | Azstarys, EVENITY, INSPIRE, PROLIA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error